Compare Organon & Co. Common Stock (OGN) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Yum China Holdings Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Yum China Holdings Inc trades at $43.53 (market cap $14.46B). The key difference: Yum China Holdings Inc is far larger — about 4× Organon & Co. Common Stock's market cap, and Yum China Holdings Inc pays the higher dividend (2.71%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Yum China Holdings Inc for 77 Days on average.
| OGN | YUMC | |
|---|---|---|
Market Cap | $3.62B | $14.46B |
Volume | 2,892,999 | 996,391 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $57.95 |
52-Week Low | $5.70 | $39.98 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.04B | $15.37B |
Dividend Yield | 0.58% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
YUMC trades at $43.2, up 0.84% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $11.8B in 2025, with a net income margin of 7.84% and strong ROE of 17.5%. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive, supported by analyst consensus of 73.68% buy ratings and a projected 25.63% upside. Risks include execution of brand integration and competitive pressures in China's restaurant sector. Earnings growth and store expansion remain key catalysts for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
